Drugs Containing Excipient (Inactive Ingredient) CELLULOSE ACETATE

« Back to Dashboard

Branded drugs containing CELLULOSE ACETATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	GLUCOTROL	glipizide	0049-0170	CELLULOSE ACETATE
Roerig	GLUCOTROL	glipizide	0049-1620	CELLULOSE ACETATE
Roerig	CARDURA	doxazosin mesylate	0049-2710	CELLULOSE ACETATE

Generic drugs containing CELLULOSE ACETATE excipient

Company	Ingredient	NDC	Excipient
Roerig	glipizide	0049-0170	CELLULOSE ACETATE
Roerig	glipizide	0049-1620	CELLULOSE ACETATE
Roerig	doxazosin mesylate	0049-2710	CELLULOSE ACETATE

Cellulose Acetate Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Suppliers, and Patent Risk

Last updated: October 4, 2026

Cellulose acetate is a specialty pharmaceutical excipient used mainly in modified-release coatings, semipermeable membranes, microencapsulation, and drug-delivery systems. Its commercial outlook is tied to controlled-release formulations rather than broad-volume tablet excipient demand. The market has stable technical demand, but financial performance is difficult to isolate because major producers report cellulose acetate within larger cellulose derivatives, specialty materials, or acetate-product segments.

The strongest commercial drivers are oral osmotic delivery, extended-release dosage forms, solvent-based coating technologies, and demand for plant-derived polymers. The principal constraints are formulation-specific development requirements, solvent handling, regulatory qualification, and competition from ethylcellulose, hypromellose, cellulose acetate phthalate, polyvinyl acetate, and aqueous coating systems.

What is cellulose acetate and how is it used in pharmaceuticals?

Cellulose acetate is a partially acetylated cellulose polymer produced by reacting purified cellulose with acetic anhydride and acetic acid. Its performance depends on degree of substitution, acetyl content, molecular weight, viscosity, particle size, and residual solvent profile.

Pharmaceutical applications include:

Application	Function of cellulose acetate	Commercial relevance
Osmotic tablets	Semipermeable membrane controlling water influx and drug release	High-value, formulation-specific
Modified-release coatings	Diffusion barrier around tablets, pellets, or particles	Established
Microencapsulation	Polymer shell controlling release	Moderate
Taste masking	Physical barrier around active ingredients	Niche
Multiparticulates	Coating of pellets and granules	Growing technical use
Transdermal or implant systems	Rate-controlling polymer layer	Specialized
Enteric or pH-responsive systems	Usually requires chemical modification, such as phthalate or trimellitate substitution	Product-dependent

Pure cellulose acetate is generally less pH-responsive than cellulose acetate phthalate or cellulose acetate trimellitate. Its principal advantage is controlled permeability, especially in semipermeable membranes. In osmotic delivery, the membrane may include a pore former, plasticizer, pigment, or other permeability modifier.

The U.S. Food and Drug Administration lists cellulose acetate and related cellulose derivatives in its Inactive Ingredient Database for specific dosage forms and routes. The database is formulation-specific and does not constitute blanket approval for every grade, supplier, impurity profile, or administration route (U.S. Food and Drug Administration [FDA], 2024a).

What pharmaceutical formulations are protected by cellulose acetate?

Cellulose acetate is most valuable where the polymer is integrated into a delivery architecture rather than used as a simple tablet filler.

Osmotic drug-delivery systems

The best-known commercial use is the semipermeable membrane in osmotic pump tablets. The polymer allows water to enter while restricting drug diffusion. The resulting release rate depends on:

• Membrane thickness
• Acetyl content and polymer permeability
• Coating weight gain
• Plasticizer concentration
• Pore-former loading
• Core osmotic pressure
• Drug solubility and dose
• Orifice size and manufacturing precision

A formulation using cellulose acetate may be protected by patents covering the membrane composition, coating process, osmotic core, laser-drilled orifice, multilayer tablet, or release profile. The excipient itself is generally not the principal source of exclusivity.

Extended-release coatings

Cellulose acetate can be applied from organic solvent systems to produce a dense film with predictable water permeability. This can be useful where aqueous coating systems do not provide sufficient barrier performance or where a specific release profile requires low polymer permeability.

Commercial development risk is higher than for conventional immediate-release coatings because the final release profile depends on multiple process variables. A supplier change can affect viscosity, acetyl substitution, molecular-weight distribution, film formation, and dissolution behavior.

Modified cellulose derivatives

Related excipients often compete directly with cellulose acetate:

Excipient	Main release function	Relative competitive position
Ethylcellulose	Water-insoluble diffusion barrier	Strong competitor in sustained release
Hypromellose	Hydrophilic gel matrix and film coating	Broadest formulation use
Cellulose acetate phthalate	Enteric protection	Used where acid resistance is required
Cellulose acetate trimellitate	Enteric and delayed-release coating	Specialized
Polyvinyl acetate	Matrix and coating polymer	Competes in extended release
Methacrylate copolymers	pH-dependent or sustained release	Strong in multiparticulates
Polyethylene oxide	Osmotic and matrix applications	Competes in high-viscosity systems

How large is the cellulose acetate pharmaceutical excipient market?

No reliable public source reports a standalone global market for pharmaceutical-grade cellulose acetate. Producers typically combine pharmaceutical cellulose acetate with industrial membranes, specialty films, cigarette-filter tow, coatings, plastics, or other cellulose derivatives.

Available market reports often estimate the broader cellulose acetate market, not the pharmaceutical-excipient segment. Those estimates should not be used as pharmaceutical revenue figures without separating:

1. Pharmaceutical excipient grades
2. Industrial film and membrane grades
3. Acetate tow
4. Plastics and molded products
5. Coatings and specialty materials

Pharmaceutical demand is likely a small portion of total cellulose acetate volume but a higher-value portion on a per-kilogram basis. The economic profile is therefore driven by qualification, consistency, technical service, and switching costs rather than commodity volume alone.

What determines pharmaceutical-grade pricing?

Price is influenced by:

• Cellulose pulp costs
• Acetic acid and acetic anhydride prices
• Energy and solvent-recovery costs
• Polymer viscosity and substitution specification
• GMP manufacturing controls
• Batch testing and documentation
• Packaging and storage requirements
• Customer qualification status
• Supply-chain geography
• Minimum order volumes

Pharmaceutical customers may pay a premium for validated grades with established compendial status, low bioburden, controlled residual solvents, consistent film performance, and regulatory-support documentation. The premium is difficult to quantify because supplier contracts are private and prices vary by grade and volume.

Which companies supply cellulose acetate for pharmaceutical use?

The supplier field includes diversified chemical companies and specialty excipient distributors. Publicly visible participants and adjacent suppliers include:

Company	Relevant position
Eastman Chemical Company	Cellulose acetate and specialty polymer producer with pharmaceutical and advanced-materials applications
Daicel Corporation	Cellulose derivatives and acetate-related materials producer
Ashland	Broad pharmaceutical excipient supplier, including cellulose-based polymers and formulation services
Colorcon	Film-coating and formulation technology provider; may supply or formulate coating systems using cellulose derivatives
Shin-Etsu Chemical	Major cellulose-derivative supplier, especially hypromellose and related pharmaceutical polymers
DuPont and specialty distributors	Historical and regional participation in pharmaceutical polymer supply chains
Regional chemical manufacturers	Increasingly relevant for cost-sensitive and dual-source procurement

The list of companies selling cellulose acetate specifically for pharmaceutical excipient use is narrower than the list of companies selling cellulose-based excipients generally. Supplier qualification must be performed at the individual grade level.

Eastman reports cellulose esters within broader business categories, while Daicel reports cellulose and acetate-related products within larger chemical and materials operations. Their public financial statements do not separately disclose pharmaceutical cellulose acetate revenue (Daicel Corporation, 2024; Eastman Chemical Company, 2024).

What is the financial trajectory for cellulose acetate producers?

The financial trajectory is mixed because cellulose acetate producers face both specialty-polymer growth opportunities and mature industrial-market exposure.

Near-term financial drivers

Pharmaceutical and healthcare demand supports margin stability because qualified excipient customers are less price-sensitive than industrial users. Growth is most likely in:

• Extended-release oral products
• Osmotic delivery systems
• Multiparticulate formulations
• Complex generics
• Long-acting drug delivery
• Higher-value pharmaceutical polymer grades

Industrial demand can be more cyclical. Cellulose acetate producers also remain exposed to acetate tow, film, membrane, plastics, and general specialty-material markets. Weakness in those segments can offset pharmaceutical growth.

Margin structure

Pharmaceutical-grade cellulose acetate generally has a better margin profile than commodity acetate products because it requires:

• Tighter process control
• Analytical release testing
• Regulatory documentation
• Audit readiness
• Change-control management
• Customer-specific technical support

The profitability of a pharmaceutical grade depends on plant utilization. A producer with underutilized capacity may face weak margins even when unit prices are high. Conversely, a qualified supplier with long-term contracts and limited competition can maintain stronger pricing.

Public-company financial visibility

Eastman reported 2023 net sales of approximately $9.6 billion and 2024 net sales of approximately $9.4 billion, but it does not report pharmaceutical cellulose acetate as a separate financial line (Eastman Chemical Company, 2024). Daicel reported consolidated sales of approximately ¥538 billion for the fiscal year ended March 31, 2024, with cellulose-related materials included within broader business reporting (Daicel Corporation, 2024).

These figures describe corporate scale, not cellulose acetate pharmaceutical revenue. They indicate that the relevant producers have diversified revenue bases and are not financially dependent on pharmaceutical excipient demand alone.

How strong is the patent estate for cellulose acetate?

The core polymer is a mature technology. Basic composition patents for conventional cellulose acetate are generally expired or commercially irrelevant. Patent value now resides in application-specific innovations.

Patent categories with continuing relevance

Patent category	Typical subject matter	Risk level
Polymer composition	Degree of substitution, viscosity, molecular weight	Low to moderate
Membrane composition	Cellulose acetate combined with plasticizers, pore formers, or additives	Moderate
Osmotic systems	Core, membrane, orifice, multilayer construction	High for specific products
Coating process	Solvent systems, spray conditions, curing, coating weight	Moderate
Release profile	Formulation and dosage regimen producing a defined release pattern	Moderate to high
Manufacturing process	Purification, acetylation, drying, and particle control	Moderate
Combination products	Polymer with active ingredient or device component	Product-specific

Patent exposure should be analyzed at the finished-drug level. A generic developer using the same excipient may still avoid infringement through different membrane thickness, pore-former concentration, coating process, tablet architecture, or release profile.

When does cellulose acetate lose exclusivity?

Cellulose acetate does not have a drug-style exclusivity period. It is an excipient, not an active pharmaceutical ingredient. There is no Orange Book exclusivity period for cellulose acetate itself, and there are no Paragraph IV challenges directed at the excipient as an independent product.

Exclusivity can arise indirectly through:

• Patents on a branded drug’s controlled-release formulation
• Method-of-use patents
• Drug-device combination patents
• Manufacturing patents
• Trade secrets covering coating parameters
• Regulatory exclusivity attached to the finished drug

The relevant expiry date is therefore the expiry of the patent covering the pharmaceutical product or formulation, not the date of first commercialization of cellulose acetate.

What is the FDA and Orange Book status of cellulose acetate?

Cellulose acetate is regulated as an inactive ingredient when used in an approved drug product. The FDA’s Inactive Ingredient Database provides precedent for use by dosage form and route, but it does not create market exclusivity (FDA, 2024a).

The Orange Book lists approved drug products and patent information submitted by sponsors. It does not generally list excipients as standalone entries. A cellulose acetate supplier does not file a Paragraph IV certification merely because its material is used in a generic formulation.

A generic applicant may need to address listed patents for the reference drug if the proposed product uses a comparable controlled-release design. That legal issue concerns the drug product’s listed patents, not cellulose acetate ownership.

What generic entry risks exist for cellulose acetate-based drugs?

Generic entry risk depends on the finished product’s formulation complexity.

Lower-risk products

Risk is generally lower where cellulose acetate is used in a conventional coating and the generic applicant can demonstrate equivalent dissolution through a different polymer or process.

Higher-risk products

Risk increases where the reference product depends on:

• A patented osmotic membrane
• A distinctive release profile
• A multilayer core
• A proprietary coating composition
• A narrow therapeutic index
• Complex in vitro-in vivo correlations
• A device-like delivery mechanism

A generic applicant can pursue several strategies:

1. Use cellulose acetate with a noninfringing composition.
2. Substitute ethylcellulose or another release-controlling polymer.
3. Change coating thickness and pore-former concentration.
4. Use a matrix tablet instead of a membrane-controlled system.
5. Challenge listed patents under Paragraph IV.
6. Wait for patent expiry and file under a less contentious pathway.

The technical challenge is often greater than the raw-material challenge. Cellulose acetate is commercially available, but reproducing the reference product’s performance may require extensive development and bioequivalence testing.

What manufacturing and intellectual-property barriers affect supply?

The key manufacturing barrier is consistency. Small changes in substitution, viscosity, moisture, or residual solvent can shift dissolution behavior. Pharmaceutical customers typically require supplier qualification, change notification, stability data, and documented manufacturing controls.

The principal supply risks are:

• Limited qualified suppliers
• Single-site production
• Regional logistics disruption
• Acetic acid and energy-cost volatility
• Solvent recovery constraints
• Changes to cellulose pulp sources
• Long customer requalification cycles
• Inconsistent grade naming across suppliers

Manufacturing know-how may be more commercially important than patent ownership. Process parameters, purification methods, and film-performance data can remain confidential even after composition patents expire.

How does cellulose acetate compare with other pharmaceutical excipients?

Cellulose acetate is strongest where a low-permeability, semipermeable membrane is required. Hypromellose has broader use because it supports immediate-release coatings, hydrophilic matrices, and many conventional oral formulations. Ethylcellulose is a strong competitor in sustained-release coatings and multiparticulates. Methacrylate polymers are preferred when pH-dependent release or enteric functionality is needed.

Cellulose acetate has a narrower addressable market but can command higher technical value in complex delivery systems. Its financial trajectory is therefore likely to track growth in controlled-release and complex-generic development rather than total oral solid-dose volume.

What licensing deals and litigation affect cellulose acetate?

Publicly disclosed licensing agreements are usually centered on finished drug technologies, osmotic delivery platforms, coating systems, or formulation patents. They rarely concern cellulose acetate as a standalone excipient.

Litigation risk typically involves:

• Branded controlled-release drugs
• Osmotic delivery patents
• Formulation patents
• Method-of-use claims
• Generic Paragraph IV filings
• Trade-secret disputes involving manufacturing or coating processes

No broad, industry-wide patent litigation trend establishes cellulose acetate as a standalone litigation category. The commercial exposure must be mapped to specific products, claims, suppliers, and jurisdictions.

Key Takeaways

• Cellulose acetate is a specialty excipient used primarily in semipermeable membranes, extended-release coatings, and multiparticulate systems.
• Pharmaceutical demand is smaller than industrial cellulose acetate demand but generally has higher value per kilogram.
• Public companies do not separately disclose pharmaceutical cellulose acetate revenue, preventing a reliable standalone market-size or profit estimate.
• Eastman and Daicel are important cellulose acetate producers; Ashland, Colorcon, Shin-Etsu, and regional suppliers compete across adjacent cellulose-based excipients.
• The core polymer is mature, while current patent value lies in osmotic systems, membrane compositions, coating processes, release profiles, and finished-drug formulations.
• Cellulose acetate has no independent Orange Book exclusivity and is not subject to standalone Paragraph IV challenges.
• Generic risk depends on the branded product’s formulation patents and the difficulty of reproducing its release profile.
• The strongest commercial outlook is in complex oral delivery, osmotic systems, controlled-release products, and formulation platforms requiring validated polymer performance.

FAQs

Is cellulose acetate an FDA-approved pharmaceutical excipient?

Cellulose acetate is listed in the FDA Inactive Ingredient Database for certain approved dosage forms and routes. Each use remains dependent on grade, amount, route, and the finished product’s regulatory submission.

Is cellulose acetate interchangeable with ethylcellulose?

No. Both can function as release-controlling polymers, but they differ in permeability, film formation, solvent compatibility, viscosity, and performance across coating conditions. Substitution normally requires formulation and regulatory assessment.

Does cellulose acetate have a USP-NF monograph?

Some cellulose derivatives have compendial monographs, but compendial status depends on the specific material and edition. A supplier’s pharmaceutical grade must be checked against the applicable USP-NF, Ph. Eur., or other regional standard.

Can a generic drug use a different polymer instead of cellulose acetate?

Yes, if the alternative formulation satisfies applicable equivalence, quality, safety, and patent requirements. A different polymer may avoid some formulation claims but can create new dissolution and bioequivalence risks.

Is pharmaceutical cellulose acetate exposed to biosimilar competition?

No. Biosimilar competition applies to biological products. Cellulose acetate is a chemical excipient. Its competitive threats come from substitute polymers, alternative delivery technologies, supplier expansion, and finished-drug generic entry.

References

1. Daicel Corporation. (2024). Integrated report 2024. Daicel Corporation.

2. Eastman Chemical Company. (2024). 2024 annual report. Eastman Chemical Company.

3. European Medicines Agency. (2017). Guideline on the quality of water for pharmaceutical use. European Medicines Agency.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, USP 47-NF 42. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

7. U.S. Food and Drug Administration. (2024c). Guidance for industry: ANDAs for certain highly variable drug products. U.S. Department of Health and Human Services.